Lyka Labs Limited (LYKALABS.NS)
INR 110.34
(-0.31%)
INR 110.34
(-0.31%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 145.95 Million INR | -51.77% |
| 2022 | 555.18 Million INR | -57.39% |
| 2021 | 1.3 Billion INR | 350.45% |
| 2020 | 289.23 Million INR | 48.02% |
| 2019 | 195.4 Million INR | -21.59% |
| 2018 | 249.21 Million INR | -7.09% |
| 2017 | 268.23 Million INR | -57.24% |
| 2016 | 627.34 Million INR | 105.86% |
| 2015 | 304.74 Million INR | -59.66% |
| 2014 | 755.39 Million INR | 36.54% |
| 2013 | 553.22 Million INR | -8.13% |
| 2012 | 602.15 Million INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 509.26 Million INR | 15.28% |
| 2009 | 441.74 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 86.67 Million INR | 52.87% |
| 2023 Q2 | 162.96 Million INR | 21.91% |
| 2023 FY | 267.75 Million INR | -51.77% |
| 2023 Q3 | 208.84 Million INR | 28.15% |
| 2023 Q1 | 133.67 Million INR | -6.51% |
| 2023 Q4 | 56.69 Million INR | -72.85% |
| 2022 Q3 | 118.3 Million INR | -18.59% |
| 2022 Q2 | 145.31 Million INR | -2.2% |
| 2022 Q1 | 148.58 Million INR | 26.74% |
| 2022 FY | 555.18 Million INR | -57.39% |
| 2022 Q4 | 142.98 Million INR | 20.87% |
| 2021 Q3 | 215.28 Million INR | -63.16% |
| 2021 Q2 | 584.43 Million INR | 51.45% |
| 2021 Q1 | 385.89 Million INR | 968.63% |
| 2021 FY | 1.3 Billion INR | 350.45% |
| 2021 Q4 | 117.23 Million INR | -45.55% |
| 2020 Q2 | 100.26 Million INR | 2.93% |
| 2020 FY | 289.23 Million INR | 48.02% |
| 2020 Q3 | 135.98 Million INR | 35.63% |
| 2020 Q4 | -44.42 Million INR | -132.67% |
| 2020 Q1 | 97.4 Million INR | 986.05% |
| 2019 Q4 | 8.96 Million INR | -85.15% |
| 2019 Q1 | 63.72 Million INR | 100.36% |
| 2019 FY | 195.4 Million INR | -21.59% |
| 2019 Q2 | 62.32 Million INR | -2.19% |
| 2019 Q3 | 60.39 Million INR | -3.1% |
| 2018 Q2 | 54.21 Million INR | -82.81% |
| 2018 Q4 | 31.8 Million INR | -63.29% |
| 2018 FY | 249.21 Million INR | -7.09% |
| 2018 Q1 | 315.36 Million INR | 0.0% |
| 2018 Q3 | 86.62 Million INR | 59.8% |
| 2017 FY | 268.23 Million INR | -57.24% |
| 2016 Q1 | 121.72 Million INR | -56.65% |
| 2016 FY | 627.34 Million INR | 105.86% |
| 2016 Q4 | 157.98 Million INR | -4.9% |
| 2016 Q3 | 166.13 Million INR | -8.47% |
| 2016 Q2 | 181.5 Million INR | 49.11% |
| 2015 Q2 | 182.37 Million INR | -19.7% |
| 2015 Q4 | 280.77 Million INR | 111.58% |
| 2015 Q3 | 132.7 Million INR | -27.24% |
| 2015 Q1 | 227.12 Million INR | 16.53% |
| 2015 FY | 304.74 Million INR | -59.66% |
| 2014 Q2 | 145.36 Million INR | 147.09% |
| 2014 Q1 | 58.82 Million INR | 0.0% |
| 2014 Q4 | 194.9 Million INR | -14.81% |
| 2014 Q3 | 228.79 Million INR | 57.4% |
| 2014 FY | 755.39 Million INR | 36.54% |
| 2013 Q3 | 59.32 Million INR | -54.14% |
| 2013 FY | 553.22 Million INR | -8.13% |
| 2013 Q1 | 118.51 Million INR | -42.16% |
| 2013 Q2 | 129.35 Million INR | 9.15% |
| 2012 Q2 | 151.32 Million INR | 8.36% |
| 2012 Q4 | 204.9 Million INR | 71.74% |
| 2012 Q3 | 119.3 Million INR | -21.16% |
| 2012 FY | 602.15 Million INR | 0.0% |
| 2012 Q1 | 139.64 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2011 Q3 | 77.34 Million INR | 0.0% |
| 2010 FY | 509.26 Million INR | 15.28% |
| 2009 FY | 441.74 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biocon Limited | 91.73 Billion INR | 99.841% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | 95.38% |
| Concord Biotech Limited | 7.56 Billion INR | 98.071% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | 97.024% |
| Jubilant Ingrevia Limited | 9.16 Billion INR | 98.408% |
| Panacea Biotec Limited | 1.42 Billion INR | 89.777% |
| Piramal Pharma Limited | 24.47 Billion INR | 99.404% |
| SMS Lifesciences India Limited | 329.57 Million INR | 55.715% |
| Supriya Lifescience Limited | 2.65 Billion INR | 94.496% |
| Syngene International Limited | 12.43 Billion INR | 98.827% |
| TAKE Solutions Limited | 183.42 Million INR | 20.427% |
| Zota Health Care Limited | 332.52 Million INR | 56.108% |